 Presentations include recently updated results from the skin cancer cohort of IGNYTE, an ongoing Phase 12 study of RP1 combined with Opdivo nivolumab, and trial-in-progress updates across the RP1, RP2 and RP3 programs Presentations include recently updated results from the skin cancer cohort of IGNYTE, an ongoing Phase 12 study of RP1 combined with Opdivo nivolumab, and trial-in-progress updates across the RP1, RP2 and RP3 programs 